FAM
MLTX icon

Fred Alger Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Fred Alger Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-295,623
Closed -$14M – 480
2025
Q2 		$14M Sell
295,623
-347,258
-54% -$14.1M 0.06% 145
2025
Q1 		$25.1M Sell
642,881
-30,892
-5% -$1.33M 0.14% 100
2024
Q4 		$36.5M Buy
673,773
+7,199
+1% +$368K 0.17% 88
2024
Q3 		$33.6M Buy
666,574
+7,545
+1% +$354K 0.16% 97
2024
Q2 		$29M Sell
659,029
-7,693
-1% -$326K 0.14% 101
2024
Q1 		$33.5M Sell
666,722
-143,864
-18% -$7.8M 0.17% 112
2023
Q4 		$49M Sell
810,586
-22,365
-3% -$1.15M 0.26% 81
2023
Q3 		$47.5M Buy
832,951
+85,346
+11% +$4.71M 0.27% 91
2023
Q2 		$38.1M Buy
747,605
+640,685
+599% +$17.2M 0.19% 119
2023
Q1 		$2.29M Buy
+106,920
New +$1.8M 0.01% 329

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fred Alger Management's MLTX Position: Q3 2025 in Review

Fred Alger Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 295,623 shares — an estimated $14M sold.

Fred Alger Management first reported a position in MLTX in Q1 2023 and held it in 10 quarters. The position peaked at $49M in Q4 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Fred Alger Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Fred Alger Management sold 295,623 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $14M.
  • Fred Alger Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 10 quarters.
  • Fred Alger Management's MoonLake Immunotherapeutics position peaked at $49M in Q4 2023.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Fred Alger Management's 13F filing for Q3 2025, filed 14 Nov 2025.